The development and implementation of safe and effective vaccines to prevent the
enormous health burden of rotavirus-associated disease is a global public health goal …

The efficacy of licensed rotavirus vaccines has only been shown against certain rotavirus
group A (RV‐A) types. It is critical to understand the burden of rotavirus gastroenteritis …

Background: Latin America will likely be the first area in the developing world where
rotavirus vaccine will be introduced into the routine childhood immunization schedule. In …

Abstract The G1P1A [8] rotavirus vaccine candidate 89‐12, the precursor to Rotarix,
stimulated high titers of neutralizing antibodies to non‐G1/P1A [8] serotypes of human …

Since the introduction of live-attenuated rotavirus vaccines in Belgium in 2006, surveillance
has routinely detected rotavirus vaccine-derived strains. However, their genomic landscape …

In the present investigation we characterized the antigenic diversity of the VP4 and VP7
proteins in 309 and 261 human rotavirus strains isolated during two consecutive epidemic …

Dual typing (VP4 and VP7) of rotavirus obtained from 257 Mexican children during three
epidemiological seasons was performed by reverse transcription-PCR. The P1G1 genotype …

The major advance in knowledge about rotavirus infection and prevention has been in
vaccine development. Several large studies of tetravalent rhesis rotavirus vaccine have had …

This study was designed to evaluate three techniques most commonly used to identify the
VP4 (P) types of human group A fecal rotaviruses. The techniques included PCR with nested …

The relative contribution of the rotavirus surface proteins, VP4 and VP7, to the induction of
homotypic as well as heterotypic neutralizing antibodies (NtAbs) in natural infections was …